{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T10:06:58Z","timestamp":1743502018322},"reference-count":33,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"no funding to report"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2022,7,3]]},"DOI":"10.1080\/14737140.2022.2088515","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T07:52:32Z","timestamp":1655193152000},"page":"695-702","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval"],"prefix":"10.1080","volume":"22","author":[{"given":"Hollis","family":"Viray","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F","family":"McDermott","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Einstein","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.007"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70465-0"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.015"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"issue":"21","key":"cit0007","first-page":"00058","volume":"2405","author":"Rizzo A","year":"2021","journal-title":"Eur Urol Focus"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4940"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32361"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101966"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30735-1"},{"key":"cit0012","first-page":"LB","volume":"68","author":"L M EFA","year":"2008","journal-title":"Cancer Res"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12197"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.3524"},{"key":"cit0015","unstructured":"Chang E, Weinstock C, Zhang L, et al. FDA approval summary: tivozanib for relapsed or refractory renal cell carcinoma. Clin Cancer Res, 2021. [cited 2021 Nov 1]. Available from; https:\/\/clincancerres.aacrjournals.org\/content\/early\/2021\/09\/22\/1078-0432.CCR-21-2334"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.120"},{"key":"cit0017","unstructured":"EMA. Fotivda [Internet]. Eur. Med. Agency. 2018 [cited 2022 May 2]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fotivda"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4869"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.03.217"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70093-7"},{"key":"#cr-split#-cit0022.1","unstructured":"Research C for DE and. FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma. FDA [Internet], 2021 [cited 2022 May 2]"},{"key":"#cr-split#-cit0022.2","unstructured":"Available from 2022 May 2: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma."},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0001"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100030"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.021"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3"},{"key":"cit0030","unstructured":"ESMO. STAR: a randomized multi-stage Phase II\/III trial of standard first-line therapy (Sunitinib or Pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and\/or metastatic RCC [Internet]. 2021. [cited 2022 May 5]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2021\/esmo-2021-kidney-cancer\/132235-esmo-2021-star-a-randomized-multi-stage-phase-ii-iii-trial-of-standard-first-line-therapy-sunitinib-or-pazopanib-comparing-temporary-cessation-with-allowing-continuation-in-the-treatment-of-locally-advanced-and-or-metastatic-rcc.html."},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.12.015"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2022.2088515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T12:34:16Z","timestamp":1656678856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2022.2088515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,3]]}},"alternative-id":["10.1080\/14737140.2022.2088515"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2022.2088515","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}